NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CRO(合同研究組織)的全球市場:自新型冠狀病毒感染(COVID-19)以來的趨勢造成的混亂

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

出版商 Frost & Sullivan 商品編碼 1008338
出版日期 內容資訊 英文 67 Pages
商品交期: 最快1-2個工作天內
價格
CRO(合同研究組織)的全球市場:自新型冠狀病毒感染(COVID-19)以來的趨勢造成的混亂 Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market
出版日期: 2021年05月13日內容資訊: 英文 67 Pages
簡介

全球CRO市場多年來一直停滯不前,但由於新型冠狀病毒感染(COVID-19)疫苗的快速研發(R&D),2020年有顯著增長。去中心化臨床試驗(DCT)開始投入實際應用,併購(M&A)和新進入者變得更加活躍。即使是小規模的 CRO 也越來越多地致力於通過開發罕見疾病的治療藥物和慢性病的生物仿製藥,以及促進功能服務提供商 (FSP) 模式的引入來發展他們的業務並確保和擴大合作夥伴。對以患者為中心和臨床試驗多樣性日益增長的興趣正在為 CRO 和技術供應商創造新的增長機會。

本報告分析了全球 CRO(合同研究機構)行業的前景和挑戰,以及 COVID-19 之後的市場前景和成熟度,整體市場規模趨勢前景,按細分市場。詳細趨勢(臨床/非臨床等))、主要的市場推動/制約因素、競爭環境、近期的重大動向(併購/資本交易等)、未來的增長機會和當前的緊迫問題等。

目錄

戰略挑戰

增長機會分析:全球 CRO 市場

  • 全球 CRO 市場:分析範圍
  • 全球 CRO 市場細分
  • 全球 CRO 市場:主要公司
  • 全球 CRO 市場:服務和利益相關者
  • 全球 CRO 市場:供應商情況
  • 全球 CRO 市場:關鍵增長指標
  • 全球 CRO 市場:增長因素
  • 全球 CRO 市場:增長抑制因素
  • 全球 CRO 市場:市場預測的先決條件
  • 全球 CRO 市場:預測市場收入
  • 全球 CRO 市場:競爭環境
  • 全球 CRO 市場:市場份額
  • 主要 CRO 的增長戰略
  • 全球 CRO 市場:併購(併購)

市場收入預測:全球 CRO 市場

  • 分析方法
  • 非臨床 CRO 市場:主要先決條件
  • 非臨床 CRO 市場:市場收入預測
  • 非臨床 CRO 市場:按細分市場預測市場收入
  • 臨床 CRO 市場:關鍵先決條件
  • 臨床 CRO 市場:市場收入預測
  • 臨床 CRO 市場:按地區預測市場收入
  • 臨床 CRO 市場:按階段預測市場收入
  • 臨床 CRO 市場:市場收入份額,按治療

市場收入預測:區域分析

  • 美洲:市場收入預測
  • 美洲:主要趨勢
  • 歐洲:市場收入預測
  • 歐洲:主要趨勢
  • 西太平洋:市場收入預測
  • 西太平洋:主要趨勢
  • 其他國家 (RoW):市場收入預測
  • 其他國家 (RoW):主要趨勢

增長機會:全球 CRO 市場

  • 增長機會:概述
  • 增長機會 (1):製藥/生物技術行業中小企業的敏捷 FSP 模型(2021 年)
  • 增長機會 (2):DCT 以確保患者多樣性和 RWE 生成(2021 年)
  • 增長機會 (3):CGT 的定制生物標誌物檢測和臨床試驗設計(2021 年)
  • 增長機會(4):針對聯合藥物和醫療器械臨床試驗的監管和數據管理服務(2021 年)

下一步

目錄
Product Code: MFFF-52

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market's maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, and estimates growth patterns for the next five years based on detailed analyses of drug and biologics interventional trials, outsourcing penetration rates, and cost variations. It further provides insights into the driving influences and challenges across regions and clinical development phases.

The plateaued CRO market experienced a sudden growth in 2020 due to the surge in research and development (R&D) efforts related to COVID-19 therapies and vaccines. The CRO market, fragmented with more than 1,000 participants, has two broad segments: nonclinical, which includes drug discovery and preclinical services, and clinical. Recent big acquisitions in the market may indicate a trend of future mergers or partnerships with integrated e-clinical platform providers as global CROs focus on building capabilities in innovative patient-centric clinical trial delivery models. Decentralized clinical trials (DCTs), while still at a nascent stage, are enabling newer participants to enter the clinical trial industry. Recent initiatives by the Decentralized Trials & Research Alliance to bring together industry participants, including CROs, pharma/biotech sponsors, and technology vendors, have increased awareness of DCTs globally and catapulted their adoption especially in North America. To adapt to DCTs, sponsors will increasingly rely on CROs to expedite the implementation of telemedicine components and remote monitoring solutions in clinical research due to inconsistencies in laws and regulations across the globe.

The rising need to maximize R&D productivity and global penetration has led to an increase in multicountry trial registrations by pharma/biotech sponsors. Several small biotech companies that support the development of therapies for rare/orphan diseases and biosimilars for chronic diseases are contributing to the CRO market growth. The continuous expansion in personalized medicine and cell and gene therapies, potency and biomarker assay complexities, and the need for adaptive trial designs is increasing outsourcing penetration to CROs. However, the shortage of skilled workforce with knowledge of the dynamic regulatory requirements to support complex therapies development can hinder the CRO market growth.

Patient-centric solutions and data-driven portfolios are fueling the adoption of functional service provider (FSP) models, even among small and midsize pharma companies. FSP partnerships enable them to rapidly scale their workforce to match business demand and distribute risk across programs or portfolios. Asia-Pacific customers are increasingly using outsourcing and insourcing FSP models in their partnerships to enhance traditional working models, resulting in greater value sharing, support, and access to expertise. Lastly, the need to develop highly efficacious therapies through innovation has boosted the growth of drug-device combination therapies, leading to more partnerships between medtech participants, CROs, and pharma companies for clinical development programs.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Global Contract Research Organization (CRO) Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis-Global CRO Market

  • Global CRO Market Scope of Analysis
  • Global CRO Market Segmentation
  • Key Competitors for the Global CRO Market
  • Global CRO Market-Services and Stakeholders
  • Global CRO Market-Vendor Landscape
  • Key Growth Metrics for the Global CRO Market
  • Growth Drivers for the Global CRO Market
  • Growth Restraints for the Global CRO Market
  • Global CRO Market-Forecast Assumptions
  • Global CRO Market-Revenue Forecast
  • Global CRO Market-Competitive Environment
  • Global CRO Market-Market Share
  • Growth Strategies of Top CROs
  • Growth Strategies of Top CROs (continued)
  • Global CRO Market-Mergers and Acquisitions

Revenue Forecast-Global CRO Market

  • Revenue Forecast Methodology
  • Nonclinical CRO Market-Key Market Assumptions
  • Nonclinical CRO Market-Revenue Forecast
  • Nonclinical CRO Market-Revenue Forecast by Segment
  • Nonclinical CRO Market-Revenue Forecast Discussion
  • Clinical CRO Market-Key Market Assumptions
  • Clinical CRO Market-Key Market Assumptions (continued)
  • Clinical CRO Market-Revenue Forecast
  • Clinical CRO Market-Revenue Forecast by Region
  • Clinical CRO Market-Percentage Revenue Forecast by Region
  • Clinical CRO Market-Revenue Forecast by Phase
  • Clinical CRO Market-Percentage Revenue Forecast by Phase
  • Clinical CRO Market-Revenue Share by Therapy
  • Clinical CRO Market-Revenue Forecast Discussion
  • Clinical CRO Market-Revenue Forecast Discussion (continued)

Revenue Forecast-Regional Analysis

  • Revenue Forecast-Americas
  • Key Trends-Americas
  • Revenue Forecast-Europe
  • Key Trends-Europe
  • Revenue Forecast-Western Pacific
  • Key Trends-Western Pacific
  • Revenue Forecast-ROW
  • Key Trends-ROW

Growth Opportunity Universe-Global CRO Market

  • Growth Opportunity Universe Summary
  • Growth Opportunity 1-Agile FSP Model for Small and Midsize Pharma/Biotech Companies, 2021
  • Growth Opportunity 1-Agile FSP Model for Small and Midsize Pharma/Biotech Companies, 2021 (continued)
  • Growth Opportunity 2-DCTs to Ensure Patient Diversity and Real-world Evidence Generation, 2021
  • Growth Opportunity 2-DCTs to Ensure Patient Diversity and Real-world Evidence Generation, 2021 (continued)
  • Growth Opportunity 3-Customized Biomarker Assays and Trial Designs for CGT, 2021
  • Growth Opportunity 3-Customized Biomarker Assays and Trial Designs for CGT, 2021 (continued)
  • Growth Opportunity 4-Regulatory and Data Management Services for Drug-Device Combination Clinical Trials, 2021
  • Growth Opportunity 4-Regulatory and Data Management Services for Drug-Device Combination Clinical Trials, 2021 (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer